Competitor Landscape: Renal Anemia

Competitor Landscape: Renal Anemia

Summary

"Competitor Landscape: Renal Anemia", briefings contain evaluations of ongoing development activities within the Renal Anemia disease markets, together with analysis of current & potential future product positioning.

Key highlights from the report -

• Roxadustat is still expected to be first HIF-PHI to launch in the EU & US markets, which may contribute to its superior uptake vs. other HIF-PHI candidates, given the current lack of clinical differentiation between candidates of this class


• In addition to progressing vadadustat’s Phase III trials in Japan, Mitsubishi Tanabe also appears focused on understanding the impact of a commonly used renal anemia strategy, iron supplementation, on the pharmacokinetics of vadadustat


• Daprodustat’s Phase III data appears to strengthen the asset’s long-term safety and efficacy profile, with daprodustat on track to become the second or third HIF-PHI approved in Japan for DD-CKD

The report comprises five key sections.

Executive Summary: Contains analysis of key market events that have occurred during the previous quarter and which have impacted the Renal Anemia landscape.

HIF-PH Inhibitors: Section contains the following analysis -

• Pipeline Landscape


• An overview of pipeline candidates, containing snapshots of current development status.


• ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.


• Expected drug-specific events & milestones until YE 2020.

ESAs & Other Therapies: Section contains the following analysis -

• Pipeline Landscape


• An overview of pipeline candidates, containing snapshots of current development status.


• ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.


• Expected drug-specific events & milestones until YE 2020.


• Approved Product Landscape


• Timeline forecasts for each approved product’s lifecycle management initiatives.


• Expected drug-specific events & milestones until YE 2020.

Iron Deficiency Anemia: Section contains the following analysis -

• Pipeline Landscape


• An overview of pipeline candidates, containing snapshots of current development status.


• ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.


• Expected drug-specific events & milestones until YE 2020.


• Approved Product Landscape


• Timeline forecasts for each approved product’s lifecycle management initiatives.


• Expected drug-specific events & milestones until YE 2020.

Appendix: Data slides containing the following information -

• Candidate ‘Watch Lists’ split by HIF-PH Inhibitors, ESAs & Other Therapies and iron deficiency anemia: early stage candidates not yet in Phase II.


• Timeline Assumptions, including standard assumptions + drug-specific assumptions for HIF-PH Inhibitors, ESAs & Other Therapies and iron deficiency anemia.

Scope

• The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)


• Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix


• Forecasts are presented in pipeline forecast figures & detailed tables


• ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy

• Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher


• Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market


• Reviews ongoing lifecycle management strategies for existing players in the market


• A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.